Content
Recent Posts
Metastatic Breast Cancer: What Changed in 2026?
For people living with metastatic breast cancer, a new treatment can mean more time before the disease gets worse or another option when existing medication stops working. This October, there are several reasons for cautious optimism. Ahead of Metastatic Breast Cancer Awareness Day on October 13, the US Food and Drug Administration (FDA) approved a new treatment combination that delayed cancer progression by a median of 8.6 months compared with existing treatment in a clinical trial. Two other approvals in September also introduced new approaches to treating certain forms of the disease. Here's what these developments mean for patients and why they matter.
Content
A New Treatment Could Keep Cancer Under Control Longer
On October 7, the FDA approved a new treatment combination for certain patients with HER2-positive metastatic breast cancer. This type of cancer produces too much of a protein called HER2, which encourages cancer cells to grow. The treatment combines tucatinib, sold as Tukysa, with two existing cancer drugs and is intended for patients whose cancer has not worsened after initial treatment.
In a clinical trial involving 654 patients, those receiving the new combination went a median of 24.9 months without their cancer progressing, compared with 16.3 months for those receiving the two existing drugs without tucatinib. Although the 8.6-month difference is encouraging, it doesn't necessarily mean patients will live that much longer overall. The treatment also carries potential side effects, including diarrhea and liver problems, which doctors must consider when deciding whether it's suitable.
Blood Tests Could Help Doctors Stay Ahead of Cancer
Some breast cancers rely on estrogen to grow, and treatments that block this hormone can slow the disease. Over time, cancer cells may develop genetic changes that make these medications less effective. One such change, known as an ESR1 mutation, can sometimes be detected through a blood test before scans show that the cancer is getting worse. This gives doctors an opportunity to consider changing treatment earlier.
In September, the FDA approved two treatments targeting cancers with this mutation. On September 4, the agency approved camizestrant, sold as Etcamah, for use alongside another cancer medication in certain patients. This hormone therapy works by breaking down estrogen receptors on cancer cells, helping slow the growth of cancers that depend on estrogen. In a clinical trial, patients who switched treatments after an ESR1 mutation was detected went approximately 16 months without their cancer progressing, compared with 9.2 months among those who continued their previous treatment.
On September 18, the FDA approved imlunestrant, sold as Inluriyo, alongside another medication for certain patients whose cancer had already progressed. An analysis of patients with ESR1 mutations found that the combination delayed disease progression longer than imlunestrant alone. Although the two treatments are intended for different patient groups, both demonstrate how identifying genetic changes can help guide cancer care.
Why Metastatic Breast Cancer Still Needs More Attention
Metastatic breast cancer, also called stage IV breast cancer, develops when cancer spreads beyond the breast to other parts of the body, such as the bones, lungs, liver, or brain. It remains incurable, although treatments can help control the disease and relieve symptoms. According to the American Cancer Society, the five-year relative survival rate for women diagnosed with breast cancer that has spread to distant parts of the body is approximately 32%, compared with more than 99% for cancer that hasn't spread beyond the breast. These figures don't predict individual outcomes, but they highlight the need for continued research.
That's why October 13 has its own place within Breast Cancer Awareness Month. While much of October focuses on screening and early detection, Metastatic Breast Cancer Awareness Day recognizes people already living with advanced disease. This year, the nonprofit METAvivor is organizing its annual #LightUpMBC campaign, with more than 325 landmarks across 20 countries and 195 cities expected to light up in teal, green, and pink. The campaign also includes a fundraising broadcast featuring patient stories and performances to support metastatic breast cancer research.
More Progress, but Still a Long Way to Go
The FDA approvals announced in 2026 mark meaningful progress, but the benefits are limited to patients with particular forms of breast cancer. Side effects, treatment costs, and access to care remain concerns, while researchers still need to determine whether these newer therapies help patients live longer overall.
As Metastatic Breast Cancer Awareness Day approaches, these developments offer reasons for cautious hope. Although a cure remains out of reach, continued research is bringing new possibilities for managing the disease and improving patients' quality of life.
For more articles like this, visit our Lifestyle News Page!